Office Hours: Adam Schoen, Brown Rudnick
Do you need expert advice on your company's IP strategy? Sign up for a free half-hour one-on-one session with Adam Schoen of the IP law firm Brown Rudnick, the afternoon of Tuesday, September 24.
Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.
If you choose a timeslot, we will require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.
If you find that you are unable to attend, you may request a refund up to 5 days in advance. (This will give us time to offer the slot to the first person on the waitlist.) We regret that we cannot honor requests made at a later time.
Where & When
Suite 214, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Tuesday, September 24, 2019
Applications are closed for this session.
About Adam Schoen
Adam Schoen has over a decade of experience representing life science and medical device companies. His practice focuses on implementation of patent strategies to further business objectives and business goals. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence and licensing. Adam works with public and private companies, investors and academic institutions.
Adam has experience across the life sciences industry, working with therapeutics companies, biologics companies, diagnostic companies and medical device companies. He works with a variety of technologies, such as small molecule therapeutics, biologics (including immunotherapeutics), next generation sequencing technologies, droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine), medical imaging technology (IVUS and OCT), mass spectrometry, digital health products, near field communication technology and semiconductor technology. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions.
Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals, Inc.